<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479580</url>
  </required_header>
  <id_info>
    <org_study_id>38RC17.215</org_study_id>
    <secondary_id>2017-A02064-49</secondary_id>
    <nct_id>NCT03479580</nct_id>
  </id_info>
  <brief_title>Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry</brief_title>
  <acronym>3CRegistry</acronym>
  <official_title>Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinique Belledonne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Mutualiste de Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Annecy Genevois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Metropole Savoie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term prognostic value of macrovascular and microvascular coronary artery stenoses in
      each type of cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery imaging techniques have taken a central role in the assessment of
      cardiovascular (CV) diagnosis over the past two decades. Many patients with a cardiomyopathy
      are also found to have a bystander coronary artery disease, not responsible for their
      cardiomyopathy. However, the prognostic value of those bystander coronary artery diseases is
      not known.

      Also, new imaging techniques have been developed to assess coronary microvascular disease,
      but the prognostic value of these findings is not known.

      In this study, the investigators evaluate the incidence and the prognosis of bystander
      coronary artery disease and microvascular disease in patients with ischemic, hypertrophic,
      dilated and restrictive cardiomyopathies in 5 French centers.

      Coronary angiography, cardiac magnetic resonance (CMR), tomographic coronary artery
      angiography, single-photon emission computed tomography (SPECT), rest and stress
      trans-thoracic echocardiography (TTE) results will be recorded.

      Macrovascular coronary artery disease is defined by :

        -  a stenosis &gt; 50 % in coronary angiography confirmed with myocardial ischemia (SPECT,
           stress echocardiography),

        -  a stenosis &gt; 70 % (50% if it is the left main coronary artery)

        -  or a stenosis 30-70 % with a fractional flow reserve (FFR) &lt; 0.8 Microvascular disease
           is defined by an index of microvascular resistance (IMR) &gt;23 or myocardial perfusion
           heterogeneity imaging (MPHI) &gt; 4 using SPECT or CMR.

      Major adverse cardiovascular events (MACE) will be assessed 1 year, 2 years and 5 years after
      enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">February 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>5 years</time_frame>
    <description>Composite outcome = rate of cardiovascular death, non-fatal myocardial infarction, need for myocardial revascularization by coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) &gt; 3 months after enrollment. During follow up</description>
  </primary_outcome>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Hypertrophic</condition>
  <condition>Ischemic</condition>
  <condition>Restrictive Cardiomyopathy</condition>
  <condition>Dilated Cardiomyopathies</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with a cardiomyopathy</intervention_name>
    <description>Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a cardiomyopathy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic

          -  Dilated

          -  Hypertrophic

          -  Restrictive cardiomyopathy.

        Exclusion Criteria:

          -  Pregnant women

          -  Breastfeeding women

          -  Patients under legal protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female and Male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles BARONE-ROCHETTE, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clémence CHARLON</last_name>
    <phone>0033476766652</phone>
    <email>ccharlon@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles BARONE-ROCHETTE, MD, PHD</last_name>
    </contact>
    <contact_backup>
      <last_name>Clémence CHARLON, ARC</last_name>
      <phone>0033476766652</phone>
      <email>ccharlon@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Matthieu CHACORNAC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loïc BELLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent DESCOTES GENON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud FLUTTAZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien GUIJARRO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin FAURIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques MONSEGU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit BERTHOUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franck BARBOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gérald VANZETTO, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muriel SALVAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Multimodal imaging</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Coronary microvascular disease</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Myocardial ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Cardiomyopathy, Restrictive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

